Could a common blood pressure pill shield the bladder from radiation damage?
NCT ID NCT05530655
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase study is testing whether lisinopril, a widely used blood pressure drug, can prevent urinary side effects in men receiving radiation for prostate cancer. Thirty men with non-metastatic prostate cancer will take one of three daily doses (5, 10, or 20 mg) during their radiation treatment. Researchers will track urinary symptoms and biomarkers to find the safest and most promising dose for future studies.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
lisinopril (an ACE inhibitor, a blood pressure drug)
What this could lead to
If it works, this could point toward a simple, low-cost way to prevent urinary problems after prostate radiation.
What could go wrong
This is a very early, small study (30 men) testing only dose safety and tolerability. It is not designed to prove effectiveness, and the drug may not reduce urinary side effects at all.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Wilmot Cancer Institute
RECRUITINGRochester, New York, 14642, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••